AstraZeneca and Mount Lebanon Hospital University Medical Center pilot use of artificial intelligence for early lung cancer detection Mount Lebanon Hospital University Medical Center is piloting a study on the use of artificial intelligence to enhance early-stage diagnosis of lung cancer, improve management and reduce mortality rates. Lung cancer is the leading cause of cancer
Read moretreated with palbociclib + ET in second and third lines (28.5% and 30.5%, respectively). Other pts received palbociclib in ≥4th lines. In 24,8% pts (26/105) palbociclib was combined with aromatase inhibitors, in other cases – with fulvestrant. Median follow-up time was 6.5 months (1.1–31.9), median progression free survival – 6.0 months (1.0–28.0). The median follow-up
Read moreDear Colleagues, Mount Lebanon Hospital – Gharios Medical Center is pleased to invite you to the “4th Lebanese Oncology Forum” on July 16 & 17, 2020 as a Webinar. Kindly today to receive link to the Webinar The Continuing Medical Education (CME) Committee of the Order of Physicians of Lebanon in Beirut designates this activity
Read moreAuthors: Joya Hadchiti , Francois G. Kamar, Jean Abi Ghosn, Mohamad Haidar, Ahmad Younes, Antoine Obeid, Marwan Haddad, Fadi Farhat, Feras Chehade Abstract Rosai-Dorfman disease (RDD), or sinus histiocytosis with massive lymphadenopathy, commonly involves the lymph nodes but may secondarily involve the skin. Purely cutaneous disease without lymphatics or internal organ involvement occurs rarely. The
Read moreZeinab Awada, Rim Abboud, and Samer Nasr Published online 2019 Jun 19 Abstract Introduction Stroke is a devastating disease, causing significant mortality and long-term disability worldwide. Since the bulk of ischemic strokes is attributed to atherothrombosis, secondary prevention with antiplatelet agents is essential to decrease the recurrence of stroke. Aspirin, as well as clopidogrel monotherapy, has been
Read moreNasr F.a,b,c · Al Ghoche A.a · Eid R.b · Nasr L.b · Diab S.a · Hallit S.c · Riachi M.d Published online: June 5, 2019 Abstract: Stage III non-small cell lung cancer is a border line stage between localized and metastatic disease. PDL-1 is gaining an important role in the therapeutic arsenal of lung cancer, the most frequent cancer worldwide. We report for the first time a
Read moreAhmad Ghoche MD, Lewis Nasr MD, Saada Diab MD, Fadi Nasr MD; Mount Lebanon Hospital, Beirut, Lebanon; Hotel Dieu De France Hospital St Joseph University, Beirut, Lebanon; Hotel-Dieu de France Saint joseph University Hospital and Holy Spirit University Kaslik, Beirut, Lebanon Published online 2019, Abstract Background: Immunotherapy targeting the PD1/PDL1 checkpoint pathway represents an important
Read moreFadi Nasr, Ahmad Al Ghoche, Saada Diab, Souheil Hallit, Moussa Riachi Published online 2019 February, Abstract Targeting the immune checkpoint of programmed death ligand 1 (PDL1) and programmed cell death protein 1 (PD-1) with immunotherapy has improved the treatment of many tumors including non small cell lung cancer (NSCLC). Checking PD-L1 status must be done during
Read more
English
Arabic
French
